It is very unlikely that Merck would take such a chance, when there is no need to do so.

marketpre
2021-10-12

It is very unlikely that $Merck(MRK)$ Merck would take such a chance, when there is no need to do so.

Read the Ridgeback and UNC paper on their Molnupiravir trial. The only death that occurred was one of the patients who had been administered a placebo. ALL of the patients on Molnupiravir were virus free by day 5, compared to 11.5% people who had virus even after day 5.

There does not appear to be doubt about whether it works - safety also does not appear to be an issue.

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法